Pfizer's $7.3B Metsera Deal Aims to Trim Lilly & Novo’s Lead in Obesity Race
Pfizer is acquiring weight-loss drug developer Metsera in a deal valued at up to $7.3 billion as it tries to catch up in the booming obesity treatment market.
More Videos
Russia Put A €100k Bounty On This Autonomous War Machine in Ukraine
Meet the autonomous tanks defending Ukraine's front lines and discover why Putin is now fighting to get a hold of one.
No Monologue, No Clicks: How Host Firings Disrupt Ad Revenue and Network Balance Sheets
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
What’s Next in Security: Wendi Whitmore’s Forecasts for 2025 Cyber Threats & Technologies
Wendi Whitmore, Chief Security Intelligence Officer at Palo Alto Networks, as she unpacks the top cybersecurity predictions.
Dodo De‑Extinction in Motion: Colossal Biosciences’ Next Frontier
Ben Lamm, founder of Colossal Biosciences, is leading a bold mission to resurrect the extinct dodo via gene editing, avian breakthroughs, and rewilding plans.
Figure’s Nasdaq Debut Signals Strong Appetite for Real‑World Asset Finance
Figure CEO Michael Tannenbaum talks IPO raising ~$787.5M and share jump on debut, spotlighting surging demand in blockchain‑powered finance.
From Seedlings to Sustainability: Vita Coco Co-Founder on Eco‑Forward Path
Mike Kirban on how Vita Coco is shaping the future of beverages with sustainable sourcing, clean labeling and environmental impact tied to growth.
